Sagent Pharmaceuticals (SGNT) Misses Q1 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sagent Pharmaceuticals (SGNT) PT Trimmed at Piper Jaffray, But 'Overweight' Maintained on Pipeline
May 4, 2016 8:50 AM EDTPiper Jaffray analyst David Amsellem lowered estimates and his price target on Sagent Pharmaceuticals (NASDAQ: SGNT) to $22.00 (from $23.00) but maintained an Overweight rating following Q1 results. While the top lined was pressured, clarity on a deep pipeline is emerging, the analyst said.
Amsellem commented, "Sagent reported 1Q16 EPS of ($0.15) on... More
RBC Capital Cuts Price Target on Sagent Pharmaceuticals (SGNT) Following Weak Cold and Flu Season
May 4, 2016 6:47 AM EDTRBC Capital maintained an Outperform rating on Sagent Pharmaceuticals (NASDAQ: SGNT), and cut the price target to $20.00 (from $28.00), following the company's 1Q earnings report. Weakness in SGNT's anti-infective business is due in part to a weak cold and flu season. This trend will... More
